TransMedics Group Inc. (TMDX) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for TransMedics Group Inc. (TMDX:NASDAQ), powered by AI.

Current Price
$75.82
P/E Ratio
13.5
Market Cap
2.6B
Sector
Healthcare
What is the TransMedics Group Inc. stock price forecast?

TransMedics Group Inc. is currently trading at $75.82. View real-time AI analysis on Alpha Lenz.

What is TransMedics Group Inc. insider trading activity?

View the latest insider trading data for TransMedics Group Inc. on Alpha Lenz.

What is TransMedics Group Inc.'s P/E ratio?

TransMedics Group Inc.'s P/E ratio is 13.5.

TransMedics Group Inc.

NASDAQ · TMDX
$75.82+0.34(+0.45%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about TransMedics Group Inc.'s future dividend policy...
Alpha Chat Insight

TransMedics Group Inc. trades at a P/E of 13.5 (undervalued) with strong ROE of 54.2%. 3Y revenue CAGR of 86.4% highlights clear growth momentum.

Ask for details

Company Overview

TransMedics Group Inc. is a medical technology company focused on the commercialization of organ transplant therapy systems. The company has developed the Organ Care System (OCS), a transformative and portable technology that replicates the conditions of the human body to preserve donor organs for transplantation. This system significantly impacts the organ transplant sector by improving the viability and availability of organs through extended preservation and transport periods. TransMedics Group Inc. primarily serves hospitals and transplant centers, addressing the critical global demand for efficient and reliable organ preservation solutions. Headquartered in Andover, Massachusetts, the company plays a pivotal role in enhancing transplant outcomes by increasing the organ pool and reducing wait times for patients. As an innovative leader in the healthcare technology market, TransMedics is critical in bridging clinical needs with cutting-edge solutions to improve patient quality of life.

CEODr. Waleed H. Hassanein M.D.
SectorHealthcare
IndustryMedical Devices
Employees728

Company Statistics

FY 2025

Profile

$2.58BMarket Cap
$605.49MRevenue
0.00Shares Out
728Employees

Margins

59.92%Gross
24.52%EBITDA
17.93%Operating
17.76%Pre-Tax
31.43%Net

Valuation

13.54P/E
5.45P/B
4.26EV/Sales
17.57EV/EBITDA
19.29P/FCF

Growth (CAGR)

86.42%Rev 3Yr
88.21%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

20.33%ROA
54.24%ROE
12.96%ROIC

Financial Health

$488.37MCash & Cash Equivalents
$106.91MNet Debt
125.82%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

TransMedics Group Inc. (ticker: TMDX) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 728 employees. Market cap is $2.6B.

The current price is $75.82 with a P/E ratio of 13.54x and P/B of 5.45x.

ROE is 54.24% and operating margin is 17.93%. Annual revenue is $605M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
TransMedics Group Inc. (TMDX) Stock Forecast 2026 $75.82 — Price, Financials & Analyst Targets | Alpha Lenz